Please login to the form below

Not currently logged in
Email:
Password:

Intuniv

This page shows the latest Intuniv news and features for those working in and with pharma, biotech and healthcare.

Shire separates out neuroscience as it considers its future

Shire separates out neuroscience as it considers its future

The company’s new neuroscience division will look to build on its ADHD heritage and newer products like Intuniv, Vyvanse and Mydayis, the latter of which was recently launched in the

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    Shire also has a foot in the non-stimulant camp with Intuniv (guanfacine), which was approved in Europe in September having been available in the US for some time - long enough

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics